HIV prevention is a pathway to global health equity
Rights-based, people-centered, evidence-informed
Ending AIDS – and preparing for future pandemics – means developing truly effective prevention that meets people where they are and delivering it expeditiously and equitably. It requires a commitment to building a comprehensive, integrated, and sustained response.
report
This issue showcases AVAC’s analysis of the recent PEPFAR data release, assessing how uptake of prevention programs—particularly PrEP initiations—have declined over the last year. As the field grapples with the lasting impact of the US government’s cuts to PEPFAR programs, AVAC takes a closer look at what the data show and what is still missing.
Blog Post
Join us Wednesday, May 20 at 10am ET for a conversation with Nicholas Enrich, author of Into the Wood Chipper and former global health lead at USAID. This webinar will provide Enrich’s inside perspective on the decisions that led to the dismantling of USAID and the foreign aid freeze and what they mean for global health today.
Blog Post
On the heels of the recent PEPFAR data release, a New York Times article this week serves as an illustration of the consequences of the US policy decisions on lives. It shows what the policy shifts, funding disruptions, and data gaps covered in this issue, look like in Zambia: strained clinics, interrupted HIV services, and uncertainty for patients and providers relying on PEPFAR.
Advocacy, communication, data and policy analysis, education
We leverage global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity.
We work with partners to develop and pursue bold national, regional, and international agendas that advance HIV prevention and global health equity and lay a solid foundation for global health security against future pandemics.
Learn more
We invest in efforts to understand potential users of prevention products, compile and analyze market data, and convene decision-makers in conversation to more effectively design products and programs that increase access to prevention options that people want and need.
Learn more
We prioritize skills-sharing and knowledge-exchange among communities, advocates, civil society, researchers, donors, policy-makers and other stakeholders, and work to cultivate and sustain dynamic partnerships that set bold and innovative agendas for HIV prevention and health equity.
Learn more
We track and translate complex science, funding and policy decisions, community advocacy and more, to make it accessible, provide context, identify gaps and opportunities for advocacy and ensure community priorities are at the center of global health.
Learn more
We champion the Good Participatory Guidelines and connect decision-makers to a network of research-savvy advocates prioritizing community voices and bring accountability to prevention science and policy.
Learn more
AVAC has begun to track the research pipeline for long-acting HIV treatment (LA-ART). A rapidly expanding pipeline for LA-ART has the potential to introduce new regimens with dosing frequencies that range from weeks to months to, eventually, years. The benefits of LA-ART include reduced drug dosing, frequency, and number of drugs, with the potential for associated decreases in the cost of medications and the burden on health systems. New drug classes could close treatment gaps in children, adolescents, and those with high viremia, comorbidities and resistance.